FDA, CDC Halt Use of Chikungunya Vaccine in Adults 60+ After Two Deaths Reported
On May 9, 2025, the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) recommended a temporary pause in the use of Ixchiq, a live virus vaccine designed to prevent chikungunya virus infection, in adults aged 60 years and older. The recommendation follows reports of serious post-marketing adverse […]
ACIP Reports on First “Do-It-Yourself at Home” Nasal Flu Shot
In September 2024, the U.S. Food and Drug Administration (FDA) licensed the first of its kind live attenuated nasal spray influenza vaccine to be administered at home during the 2024-2025 “flu season.” Adults up to the 49 years of age are eligible to self-administer the FluMist Home vaccine or give it to their children aged […]
Autism Epidemic ‘Unprecedented in Human History,’ Now Reaches 1 in 31 Kids in America
On Apr. 15, 2025, the U.S. Centers for Disease Control and Prevention (CDC) published an analysis in its epidemiological digest Morbidity and Mortality Weekly Report (MMWR) which found the prevalence of autism spectrum disorder (ASD) among children eight years old in the United States to be 1 in 31 (3.2 percent).1 2 3 4 5 […]
Flu Shot Recipients “More Likely” to Get Influenza Than Unvaccinated
The American Medical Association (AMA) cites that the influenza vaccine is estimated to be 40-60 percent effective at preventing serious infections or death from the influenza virus that affects up to 40 million Americans every year. However, for the 2024-2025 flu “season” the influenza vaccine not only missed the mark on effectiveness, but is linked […]
U.S. Government Accused of Hiding Deadly E. Coli Outbreak
A deadly E. coli outbreak reportedly linked to food was kept hidden by the U.S. government health agencies according to a new lawsuit. The California legal case alleges that a November 2024 E. coli outbreak sickened 89 people in 15 states.1 One person died while 36 others were hospitalized, including a nine-year-old boy who suffered […]
Moderna Continues mRNA Norovirus “Vaccine” Trials Following Guillain-Barré Case
A first-ever norovirus “vaccine”—another experimental biological product produced by Moderna, Inc., using novel mRNA technology—may be on the horizon even though last month the U.S. Food and Drug Administration (FDA) paused Moderna’s late-stage clinical trial following a report of Guillain-Barré syndrome (GBS), a rare neurological side effect that has also surfaced in its RSV vaccine […]